Continuing production of medically necessary products (MNPs) in the event of a pandemic will be made easier by developing a contingency plan, according to the FDA which has issued guidance on the subject.
Researchers have discovered a series of enzyme inhibitors that
appear to block the replication of the SARS virus - a finding that
could help speed up the research and development of drugs used to
treat the killer virus.
Researchers in Japan have discovered a nickel-alloy coating with
antibacterial properties, which is believed to be effective at
reducing the SARS coronavirus. The use of this antibacterial
material has the potential to radically alter...
The outbreak of severe acute respiratory syndrome (SARS) earlier
his month in China may have been contained, but it serves as a
timely reminder of the need for continued efforts to develop drugs
and vaccines for the virus, reports...
There are renewed concerns of another severe acute respiratory
syndrome (SARS) epidemic after the Chinese Ministry of Health
reported three more cases, including one death. This brings the
current number of people with SARS-like symptoms...
Researchers in France have isolated the three-dimensional structure
of a protein essential for the replication of the virus that causes
severe acute respiratory syndrome (SARS) which could represent a
new drug target for the disease.
Virologists in China have said that a man suffering from fever and
a respiratory infection is infected with severe acute respiratory
syndrome (SARS), the viral disease that caused nearly 800 deaths
around the world in the first half...
There are fears that a renewed epidemic of severe acute respiratory
syndrome (SARS) could occur in 2004, after initial tests on a
patient with symptoms associated with the disease suggested that
the causative agent was the SARS coronavirus...
Abbott Laboratories and artus have gained European approval for
their RealArt HPA Coronavirus LC RT Reagents, a diagnostic test for
Severe Acute Respiratory Syndrome (SARS).
UK life sciences group Amersham has reported first-quarter 2003
sales of £381 million (€544m), flat on the same period of 2002 but
up 6 per cent if unfavourable currency impacts and discontinued
product sales were excluded. The results...
